Cowen and Company reiterates Buy on Aldeyra Therapeutics (NASDAQ:ALDX)

Analyst ratings on Aldeyra Therapeutics (NASDAQ:ALDX)

Story continues below

There are currently 4 analysts ratings on Aldeyra Therapeutics with a consensus rating of Buy and a consensus price of $16 (133.58% upside).

Consensus estimate

The consensus estimates for Aldeyra Therapeutics (NASDAQ:ALDX) for the current year are $-1.71 EPS  and for the following year are $-1.9 EPS.

Recent analyst ratings on Aldeyra Therapeutics

The most recent analyst ratings for Aldeyra Therapeutics include:

Date Firm Action Rating Price Target
11/15/2016 Cowen and Company Reiterated Rating Buy
9/26/2016 HC Wainwright Initiated Coverage Buy $18.00
7/1/2016 Stifel Nicolaus Initiated Coverage Buy $16.00
2/29/2016 Janney Montgomery Scott Reiterated Rating Buy
11/13/2015 Canaccord Genuity Reiterated Rating Buy $15.00
3/25/2015 Chardan Capital Initiated Coverage Buy $16.00

Recent Insider Trades for Aldeyra Therapeutics

The most recent insider trades for Aldeyra Therapeutics (NASDAQ:ALDX) include:

Transaction Date Insider Name Title Buy/Sell Number of Shares Average Share Price Total Transaction
5/26/2016 Perceptive Advisors Llc Major Shareholder Buy 700,000 $5.00 $3,500,000.00
10/26/2015 Perceptive Advisors Llc Major Shareholder Buy $50,000.00 $6.46 $323,000.00
10/22/2015 Perceptive Advisors Llc Major Shareholder Buy 18,020 $6.47 $116,589.40
10/20/2015 Perceptive Advisors Llc Major Shareholder Buy 37,145 $6.39 $237,356.55
8/7/2014 Martin Joseph Joyce Director Buy $1,000.00 $3.95 $3,950.00
8/6/2014 C. Boyd Clarke Director Buy 3,000 $3.69 $11,070.00
5/7/2014 C. Boyd Clarke Director Buy 12,500 $8.00 $100,000.00


About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Recent Trading activity for Aldeyra Therapeutics

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) closed the previous trading session at $6.85 (up) (0.52) (8.30%) with (19.645K) shares trading hands.

An ad to help with our costs